fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Poor gut health connected to severe COVID-19

Written by | 22 Jan 2021

People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems.

EU approved 96 new medicines in 2020

Written by | 14 Jan 2021

The European Medicines Agency gave its backing to 15 new medicines at its December meeting, taking its total for the year to 96.

Diabetes drug canagliflozin slows advanced kidney disease

Written by | 2 Jan 2021

Article written by Bruce Sylvester The diabetes drug canagliflozin, which has already shown efficacy in slowing kidney disease, is also effective among patients with advanced kidney disease.

Hydroxychloroquine is heart-safe for lupus patients, including those with kidney disease

Written by | 4 Dec 2020

Article written by Bruce Sylvester Hydroxychloroquine treatment for lupus has no significant impact on heart rhythm, researchers reported on Nov 2, 2020 at the American College of Rheumatology/ACR… read more.

Dapagliflozin shows efficacy in chronic kidney disease

Written by | 23 Nov 2020

Article written by Bruce Sylvester Patients with chronic kidney disease have achieved improved outcomes with dapagliflozin treatment, researchers reported on October 8, 2020 in the NEJM/New England Journal… read more.

Combination treatment appears optimal for high-risk elevated LDL patients

Written by | 8 Sep 2020

Article written by Bruce Sylvester Researchers from a large European study, which included the UK, report that while patients are often able to reduce risks of cardiovascular events… read more.

Results from phase III DAPA-CKD trial of Farxiga met primary and secondary endpoints to treat chronic kidney disease – AstraZeneca.

Written by | 29 Jul 2020

AstraZeneca announced high-level results from Farxiga’s (dapagliflozin) Phase III DAPA-CKD trial showed a statistically significant and clinically meaningful effect on its primary endpoint of a composite of worsening… read more.

FDA accepts filing of NDA for voclosporin as a treatment for lupus nephritis.- Aurinia Pharma

Written by | 22 Jul 2020

Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that the FDA has accepted the filing of its New Drug Application… read more.

PT 20 iron-based phosphate binder study is published in Nephrology Dialysis Transplantation.-Shield Therapeutics

Written by | 17 Jul 2020

Shield Therapeutics plc a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), notes the recent publication in Nephrology… read more.

Advisory Committee Meeting recommends terlipressin to treat adults with hepatorenal syndrome type 1.- Mallinckrodt

Written by | 16 Jul 2020

Mallinckrodt Plc announced that the Cardiovascular And Renal Drugs Advisory Committee of the U.S. FDA voted to recommend approval for its investigational agent terlipressin to treat adults with… read more.

Green light for 8 new medicines

Written by | 15 Jul 2020

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended eight medicines for approval at its June 2020 meeting.

Phase III study FIDELIO-DKD of BAY 94 8862 meets primary endpoint in diabetic kidney disease.- Bayer

Written by | 11 Jul 2020

The Phase III study FIDELIO-DKD evaluating the efficacy and safety of BAY 94 8862 (finerenone), from Bayer, versus placebo when added to standard of care for chronic kidney… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.